Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03012165 · ClinicalTrials.gov registry record · Phase 2
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT03012165 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 154 participants.
The verdict
NCT03012165, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.
Interventions
- DRUG ADX-102 Ophthalmic Drops (0.5%)
- DRUG ADX-102 Ophthalmic Drops (0.1%)
- DRUG Vehicle of ADX-102 Ophthalmic Drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03012165
The ClinicalTrials.gov registry entry for NCT03012165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ADX-102 Ophthalmic Drops (0.5%) is the first listed.
NCT03012165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03012165 about?
NCT03012165 is a clinical study titled "A Study of ADX-102 in Subjects With Allergic Conjunctivitis". A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.
What is the current status of trial NCT03012165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2016-12. Estimated completion is 2017-05.
What interventions are being tested in trial NCT03012165?
The interventions under investigation include: ADX-102 Ophthalmic Drops (0.5%) (DRUG), ADX-102 Ophthalmic Drops (0.1%) (DRUG), Vehicle of ADX-102 Ophthalmic Drops (DRUG).
Who is sponsoring clinical trial NCT03012165?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.